EQT’s Proposed QIAGEN Takeover Values the Transaction at Approximately €9.6 Billion

On 21 October, EQT’s acquisition vehicle announced a voluntary cash offer of €46.50 per QIAGEN share, valuing the Dutch-headquartered life-sciences company’s equity at approximately €9.6 billion. The proposed takeover remains subject to the offer process and applicable conditions; the reported figure is the proposed equity value, not a completed cash payment. Banks, investors and financial advisers can explore valuation modelling, portfolio-risk analysis and transaction forecasting, while HPC can support data-intensive financial workloads through a project-specific quotation.

If you are interested to enquire further, please fill in the form below with your details and one of our consultants will contact you shortly.